Want to see ROIV full AI Analyst Report?
ROIV Stock Chart & Stats
$36.47
-$0.09(-0.26%)
At close: 4:00 PM EDT
$36.47
-$0.09(-0.26%)
Day’s Range― - ―
52-Week Range$13.81 - $42.50
Previous CloseN/A
Volume4.04M
Average Volume (3M)7.76M
Market Cap
$29.49B
Enterprise Value$22.46K
Total Cash (Recent Filing)$3.84B
Total Debt (Recent Filing)$107.15M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 16, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding722,323,000
10 Day Avg. Volume11,298,587
30 Day Avg. Volume7,761,598
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$45.56Price Target Upside24.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.39
Revenue Forecast (FY)$52.87M
Bulls Say, Bears Say
Bulls Say
FDA-approved Commercial ProductLISRAYA gives Roivant an approved commercial product in an underserved rare disease, moving the company beyond pipeline development. Its targeted oral profile, symptom benefits, and steroid-sparing evidence can support durable physician adoption and establish a foundation for broader commercial execution.
Positive PH-ILD Clinical MomentumMosliciguat’s positive Phase 2 results and transition into the global Phase 3 PHrontier study expand Roivant’s potential future product base. Meaningful improvements across pulmonary vascular resistance, walking distance, and NT-proBNP strengthen the case for continued development in a high-unmet-need market.
Strong Balance Sheet FlexibilityVery low leverage and a large equity base provide Roivant with substantial flexibility to fund clinical programs, support launches, and absorb development setbacks. This financial capacity is especially valuable for a biotechnology company with multiple programs advancing simultaneously and limited current profitability.
Bears Say
Substantial Ongoing Cash BurnPersistent operating and free-cash-flow deficits mean Roivant is consuming significant cash while funding its pipeline and commercial buildout. Continued burn can reduce financial flexibility over time and leave future investment capacity dependent on its balance sheet, product launches, or additional partnering and monetization activity.
Declining Revenue And Sustained LossesDeclining revenue alongside sizable net and operating losses indicates that Roivant has not yet converted its development portfolio into predictable earnings power. Although gross margins are strong, the cost base remains too high, creating uncertainty around the timing and sustainability of operating leverage.
Clinical And Commercial Adoption RiskSeveral pipeline programs still face clinical and statistical uncertainty, including placebo variability and questions about translating mosliciguat’s effects into PH-ILD outcomes. Separately, JAK-class safety perceptions may constrain physician or payer adoption of LISRAYA, increasing execution risk after approval.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $13.81 and its highest was $42.50 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $29.49B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Nov 16, 2026 which is in 62 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Aug 06, 2026. The company reported -$0.335 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.035.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.37.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 722,323,000 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.335 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went up 1.503%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.56 (24.93% Upside)
$45.56 (24.93% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 60%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 5.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $240.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
191.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Roivant Sciences
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$45.56
▲(24.93% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Incyte
―
Jazz Pharmaceuticals
―
Neurocrine
―
Ascendis Pharma
―
Ownership Overview
18.85% Insiders
16.93% Mutual Funds
22.14% Other Institutional Investors
26.34% Public Companies and
Individual Investors